# A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Source: https://onco.cc/trials/nct07172919/  
OnCo record `nct07172919` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sotorasib and Panitumumab in advanced solid tumours, run by Amgen, now recruiting.

## Summary

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation is a phase 2 interventional study registered as NCT07172919 by Amgen, with 14 participants planned, started 2026-01-02 and due to reach its primary completion in 2028-07-01. Interventions recorded: Sotorasib and Panitumumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07172919
- Phase: 2
- Setting: A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study
- Sponsor: Amgen
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT07172919: https://clinicaltrials.gov/study/NCT07172919

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Panitumumab](https://onco.cc/drugs/panitumumab/), [Sotorasib](https://onco.cc/drugs/sotorasib/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct07172919.json